ArticleAdvances in therapy2026
An Examination into the Anti-stress and Anti-fatigue Effects of an Ashwagandha Extract (Ashwa.30™) in Stressed Adults: A Randomised, Double-Blind, Placebo-controlled Trial.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAshwagandha supplementation has been associated with reduced self-reported stress and anxiety, although most trials have used doses of 250-600 mg daily for 6-8 weeks. This study examined the effects of a low-dose ashwagandha extract (Ashwa.30™) on perceived stress, mood, fatigue, and stress reactivity in stressed adults.
methodsIn this 28-day, randomised, double-blind, placebo-controlled trial, 60 adults aged 18-65 years with self-reported stress were randomly allocated to receive ashwagandha 30 mg/day or placebo. Outcomes included the Depression, Anxiety, and Stress Scale, daily mood ratings, and the Chalder Fatigue Scale. The Socially Evaluated Cold-Pressor Test (SECPT) was conducted on Days 7 and 28, with subjective stress and fatigue, cardiovascular and electrodermal measures, skin temperature, and salivary cortisol and chromogranin A assessed.
resultsCompared to the placebo, ashwagandha intake was associated with greater reductions in self-reported stress in the full analysis set (primary analysis; p = 0.046). The per protocol set analysis was directionally consistent but not statistically significant. Mean daily stress ratings were also lower in the ashwagandha group (p = 0.043). During the Day 28 SECPT, the ashwagandha group reported lower stress ratings (p = 0.044), and salivary cortisol concentrations remained relatively stable in the ashwagandha group but increased in the placebo group, suggesting attenuation of cortisol reactivity (p = 0.047). However, no statistically significant between-group differences were detected for other secondary and physiological outcomes.
conclusionsAn ashwagandha extract (Ashwa.30™) administered at 30 mg daily was associated with reduced self-reported stress in the Full Analysis Set and attenuation of SECPT-related salivary cortisol reactivity. These preliminary findings support further investigation in larger, adequately powered trials.
trial registrationAustralian and New Zealand Clinical Trials Registry: (ACTRN12625000129482) https://www.anzctr.org.au/ACTRN12625000129482p.aspx .
Indexed as
Identifiers
42593642What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.